Abstract
The cardiovascular therapeutic area has historically provided the largest
single source of revenue for the pharmaceutical industry. The outlook for the
market remains robust, driven by high patient populations and a widespread
focus on preventative treatment. However, low growth rates in established
indications will prevail due to the growing availability of effective generic
medicines and an overall scarcity of innovative new drug launches. With
product launches in mainstream cardiovascular indications facing continued
difficulties, major pharma companies are now primarily focusing efforts upon
compliance and protection against the generic threats posed by line extensions
and combination treatments. Changes in the competitive positions of leading
companies will become inevitable as new revenue sources continue to decline
and established portfolios underperform. The Cardiovascular Market Outlook to
2012 is a new report published by Business Insights that provides
comprehensive coverage of every class of drugs across all major cardiovascular
indications. Detailed insights into recent key events and future market
leaders are also provided, in addition to epidemiological analysis and
forecasts for major products over the period 2007-12. With coverage of over
90% of the total market for cardiovascular products, this report profiles the
underlying trends and factors driving the market and identifies the most
promising areas of potential growth. Discover the key market trends and growth
drivers of the cardiovascular market, assess the competitive dynamics of
leading companies and evaluate the future prospects of major products with
this new report...
View Cart
